Insight Brief
Victor Weigman, Ph.D. | August 01, 2017

Using Gene Signature Methodologies to Strengthen Immuno-Oncology Trials

Genomic technologies that empower and enhance immuno-oncology trials
Q2 Solutions supports the battle against cancer by offering a number of services to support clinical trials. These offerings include cutting edge genomics technologies to power and enhance immuno-oncology (IO) trials where reporting transcriptional response pairs a person to therapy without multiple biopsies. This kind of approach extends treatment utility because of it enables continual refinement of the most useful biomarkers found within the trial results.

In this insight brief, learn how we leverage gene signature methodologies to strengthen immuno-oncology trials, as well as 8 genomic applications that help elucidate the complex interactions between an individual's cancer and their immune system.

Victor Weigman, Ph.D., Director, Translational Genomics

Related Services:
The End to End Importance of Selecting the Right Biomarker in Cancer Studies

A critical component in the fight against cancer and optimizing treatment outcomes for patients

Clinical Trials Laboratories in the Immuno-Oncology Setting

Increased demands lead to increased opportunities

Read More